Table of Contents

Section One Hormone Therapy

Chapter 1 Cell Biology of Prostate Cancer and Molecular Targets
  Martin E. Gleave, Michael K. Cox, Yuzhuo Wang

Chapter 2 Luteinizing Hormone-Releasing Hormone (LH-RH) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer
  Andrew V. Schally and Norman L. Block

Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer
  Hannelore V. Heemers and Donald J. Tindall

Chapter 4 Androgens and Prostate Cancer
  Douglas K. Price and Ann W. Haing

Chapter 5 Androgen Receptor Biology in Prostate Cancer
  Edward P. Gelmann

Chapter 6 Androgen Receptor Antagonists
  Howard C. Shen, Mary-Ellen Tadini, Steven P. Balk

Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer
  Zoran Culig

Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer
  Terence W. Friedlander and Charles J. Ryan

Chapter 9 Androgen Deprivation Therapy
  Nima Sharifi

Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway
  Francine Zanchetta Coelho Marques and Juergen Reichardt

Section Two Chemotherapy

Chapter 11 Mitoxantrone
  Patricia Halterman, Nicholas J. Vogelzang, Alireza Farahzad, Oscar B. Goodman, Jr.

Chapter 12 Docetaxel
  Courtney K. Phillips and Daniel P. Petrylak

Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
  Jonathan Rosenberg

Chapter 14 Platinum Agents in Prostate Cancer
  Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh

Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer
  Tristan M. Sissung and William D. Figg

Chapter 16 Microtubule Targeting Agents
  Antonio Tito Fojo and David E. Adelberg

Section Three Angiogenesis

Chapter 17 Principles of Antiangiogenic Therapy
  Cindy H. Chau and William D. Figg

Chapter 18 Bevacizumab in Advanced Prostate Cancer
  Aymen A. Elfiky and William Kevin Kelly

Chapter 19 Thalidomide and Analogs
  Erin R. Gardner, Giuseppe Di Lorenzo, and William D. Figg

Chapter 20 Investigational Angiogenesis Inhibitors
  Joanny B. Aragon-Ching, William Dahut, MD

Chapter 21 Pharmacogenetics of Angiogenesis
  Guido Bocchi, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi

Section Four Bone Metastasis

Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis
  Evan T. Keller and Christopher L. Hall

Chapter 23 Radiopharmaceuticals
  Oliver Sartor and Damerla R. Venugopal

Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases
  Phillip J. Saylor and Matthew R. Smith

Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer
  Joel B. Nelson

Chapter 26 Calcitriol and Vitamin D Analogs
  Ana R. Jensen, Russell S. Smulewitz, Tomasz M. Beer, Edwin M. Posadas

Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches
  Raviv A. Madan, James L. Gulley, Jackie Celestin, Philip M. Aten, Jeffrey Schum

Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer
  Celestia S. Higano and Mark W. Frohlich

Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX